| Dr Thomas Cassidy, DO | |
|
489 State St, Bangor, ME 04401-6616 | |
| (207) 973-7000 | |
| (207) 973-5042 |
| Full Name | Dr Thomas Cassidy |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 18 Years |
| Location | 489 State St, Bangor, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518168327 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2173 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eastern Maine Medical Center | Bangor, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eastern Maine Medical Center | 2062315161 | 577 |
News Archive
Indonesia the nation worst hit by bird flu is clearly struggling to cope with the deadly virus but has now joined with close neighbour Singapore to control the spread of the H5N1 virus.
Micro Imaging Technology, Inc. today announced that it has changed is company name to Micro Identification Technologies to better reflect the extensive capabilities of its ID technology software.
More than 90 percent of people caring for a family member with dementia experience poor sleep, according to new research by the University at Buffalo School of Nursing.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
› Verified 4 days ago
| Entity Name | Eastern Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790789147 PECOS PAC ID: 2062315161 Enrollment ID: O20040128000088 |
News Archive
Indonesia the nation worst hit by bird flu is clearly struggling to cope with the deadly virus but has now joined with close neighbour Singapore to control the spread of the H5N1 virus.
Micro Imaging Technology, Inc. today announced that it has changed is company name to Micro Identification Technologies to better reflect the extensive capabilities of its ID technology software.
More than 90 percent of people caring for a family member with dementia experience poor sleep, according to new research by the University at Buffalo School of Nursing.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Cassidy, DO 43 Whiting Hill Rd, Ste 300, Brewer, ME 04412-1005 Ph: (207) 973-5035 | Dr Thomas Cassidy, DO 489 State St, Bangor, ME 04401-6616 Ph: (207) 973-7000 |
News Archive
Indonesia the nation worst hit by bird flu is clearly struggling to cope with the deadly virus but has now joined with close neighbour Singapore to control the spread of the H5N1 virus.
Micro Imaging Technology, Inc. today announced that it has changed is company name to Micro Identification Technologies to better reflect the extensive capabilities of its ID technology software.
More than 90 percent of people caring for a family member with dementia experience poor sleep, according to new research by the University at Buffalo School of Nursing.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
› Verified 4 days ago
Dr. Leonard C Moneke, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-7000 Fax: 207-973-5042 | |
Dr. James M Mccarthy, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-7000 Fax: 207-973-5042 | |
Dr. Alexandra Craig, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 992 Union St, Bangor, ME 04401 Phone: 207-945-5247 | |
Dr. Savitha Rajan, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-7000 Fax: 207-973-5042 | |
Pradeep S Paul, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 360 Broadway, Bangor, ME 04401 Phone: 207-907-3215 Fax: 207-907-1795 | |
Toyiba Hussain Syed, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-6252 Fax: 207-973-5042 | |
Keith Amit Singh, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-6605 Fax: 207-973-4441 |